Email updates

Keep up to date with the latest news and content from Multidisciplinary Respiratory Medicine and BioMed Central.

Open Access Highly Accessed Open Badges Review

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?

Sabina A Antoniu

Author Affiliations

Pulmonary Disease-Medicine II Department, University of Medicine and Pharmacy Grigore T Popa, Pulmonary Disease University Hospital, 30 Dr I CihacStr, Iasi, 700115, Romania

Multidisciplinary Respiratory Medicine 2012, 7:41  doi:10.1186/2049-6958-7-41

Published: 12 November 2012


Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various pathways driven by proinflammatory/profibrogenetic mediators such as platelet -derived growth factor, vascular endothelial growth factor or basic fibroblast growth factor. Given their prominent pathogenic roles in this disease such growth factor might be suitable therapeutic targets.In fact, the existing preclinical and clinical data demonstrated that their therapeutic inhibition results in a delayed progression of the pulmonary fibrosis and in the improvement of the disease outcome. BIBF 1120 is a potent triple blocker of the receptors of these growth factors which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. This review discusses the existing data supporting its potential use in this disease.

Basic fibroblast growth factor; Idiopathic pulmonary fibrosis; Inhibitor; Platelet derived-growth factor; Tyrosine kinase; Vascular endothelial growth factor